MWM
RUBY

Mascoma Wealth Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Mascoma Wealth Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$175 – 634
2022
Q4 		$175 Hold
1,000
– – ﹤0.01% 615
2022
Q3 		$0 Hold
1,000
– – ﹤0.01% 640
2022
Q2 		$1K Buy
1,000
+750
+300% +$1.26K ﹤0.01% 598
2022
Q1 		$1K Hold
250
– – ﹤0.01% 578
2021
Q4 		$2K Buy
250
+150
+150% +$2.08K ﹤0.01% 506
2021
Q3 		$2K Buy
+100
New +$2.17K ﹤0.01% 426
2021
Q2 		– Sell
-100
Closed -$3K – 458
2021
Q1 		$3K Buy
+100
New +$1.46K ﹤0.01% 413

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Mascoma Wealth Management's RUBY Position: Q1 2023 in Review

Mascoma Wealth Management sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 1,000 shares — an estimated $175 sold.

Mascoma Wealth Management first reported a position in RUBY in Q1 2021 and held it in 7 quarters. The position peaked at $3K in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Mascoma Wealth Management reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Mascoma Wealth Management sold 1,000 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $175.
  • Mascoma Wealth Management first reported a position in Rubius Therapeutics, Inc in Q1 2021 and held it in 7 quarters.
  • Mascoma Wealth Management's Rubius Therapeutics, Inc position peaked at $3K in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Mascoma Wealth Management's 13F filing for Q1 2023, filed 1 May 2023.